Wuhan HVSEN Biotechnology 回盛生物
20 significant filings since 31 May 2026: 10 on buyback, 5 on guarantee or financial assistance and 3 on dividend, and 2 other kinds. The latest, on 9 Sep 2026: 关于控股股东、实际控制人之间内部转让股份计划的预披露公告.
自 31 May 2026 起有 20 份重大公告：buyback 10 份、guarantee or financial assistance 5 份、dividend 3 份，另有 2 类。最新一份（9 Sep 2026）：关于控股股东、实际控制人之间内部转让股份计划的预披露公告。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 6 Sep 2024 | 国信证券 | 鲁家瑞,李瑞楠,江海航 | Buy 买入 | ▼ | Outperform 增持 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 西南证券 | 徐卿,赵磐 | Buy 买入 | 19 Aug 2026 | 2 | — |
| 中航证券 | 陈翼,彭海兰 | Buy 买入 | 21 Jul 2026 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 3 reports. 每行为该券商近十二个月的最新研报；3 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。